Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Inflammatory Bowel Diseases

  Free Subscription


27.03.2017

7 Aliment Pharmacol Ther
1 Am J Surg
1 BMC Gastroenterol
1 Dig Dis
1 Dig Dis Sci
5 Inflamm Bowel Dis
1 J Clin Microbiol
14 J Crohns Colitis
2 J Gastroenterol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Aliment Pharmacol Ther

  1. CHOLAPRANEE A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, et al
    Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
    Aliment Pharmacol Ther. 2017 Mar 22. doi: 10.1111/apt.14030.
    PubMed     Text format     Abstract available

  2. AKSAN A, Isik H, Radeke HH, Dignass A, et al
    Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Mar 21. doi: 10.1111/apt.14043.
    PubMed     Text format     Abstract available

  3. JAIRATH V, Casteele NV, Hindryckx P
    Letter: dose optimising infliximab in acute severe ulcerative colitis - authors' reply.
    Aliment Pharmacol Ther. 2017;45:1170-1171.
    PubMed     Text format    

  4. CHOY MC, De Cruz P
    Letter: dose optimising infliximab in acute severe ulcerative colitis.
    Aliment Pharmacol Ther. 2017;45:1169-1170.
    PubMed     Text format    

  5. ANGELISON L, Marsal J, Hertervig E
    Letter: how to define remission in ulcerative colitis - histological remission should be considered. Authors' reply.
    Aliment Pharmacol Ther. 2017;45:1177-1178.
    PubMed     Text format    

  6. KILINCALP S, Ustun Y, Simsek Z
    Letter: how to define remission in ulcerative colitis - histological remission should be considered.
    Aliment Pharmacol Ther. 2017;45:1177.
    PubMed     Text format    

  7. SEOW CH, Leung Y, Vande Casteele N, Ehteshami Afshar E, et al
    The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Mar 20. doi: 10.1111/apt.14040.
    PubMed     Text format     Abstract available


    Am J Surg

  8. SANGSTER W, Berg AS, Choi CS, Connelly TM, et al
    Outcomes of early ileocolectomy after percutaneous drainage for perforated ileocolic Crohn's disease.
    Am J Surg. 2016;212:728-734.
    PubMed     Text format     Abstract available


    BMC Gastroenterol

  9. ONO Y, Kanmura S, Morinaga Y, Oda K, et al
    The utility of apoptosis inhibitor of macrophages as a possible diagnostic marker in patients with Crohn's disease.
    BMC Gastroenterol. 2017;17:40.
    PubMed     Text format     Abstract available


    Dig Dis

  10. ELIADOU E, Kini G, Huang J, Champion A, et al
    Intravenous Iron Replacement Improves Quality of Life in Hypoferritinemic Inflammatory Bowel Disease Patients with and without Anemia.
    Dig Dis. 2017 Mar 24. doi: 10.1159/000468145.
    PubMed     Text format     Abstract available


    Dig Dis Sci

  11. BENGTSON MB, Martin CF, Aamodt G, Vatn MH, et al
    Inadequate Gestational Weight Gain Predicts Adverse Pregnancy Outcomes in Mothers with Inflammatory Bowel Disease: Results from a Prospective US Pregnancy Cohort.
    Dig Dis Sci. 2017 Mar 22. doi: 10.1007/s10620-017-4547.
    PubMed     Text format     Abstract available


    Inflamm Bowel Dis

  12. NAVIGLIO S, Parentin F, Nider S, Rassu N, et al
    Ocular Involvement in Children with Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2017 Mar 21. doi: 10.1097/MIB.0000000000001079.
    PubMed     Text format     Abstract available

  13. NGUYEN GC, Murthy SK, Bressler B, Lam MC, et al
    Quality of Care and Outcomes Among Hospitalized Inflammatory Bowel Disease Patients: A Multicenter Retrospective Study.
    Inflamm Bowel Dis. 2017 Mar 21. doi: 10.1097/MIB.0000000000001068.
    PubMed     Text format     Abstract available

  14. KHAN N, Patel D, Shah Y, Lichtenstein G, et al
    A Novel User-Friendly Model to Predict Corticosteroid Utilization in Newly Diagnosed Patients with Ulcerative Colitis.
    Inflamm Bowel Dis. 2017 Mar 21. doi: 10.1097/MIB.0000000000001080.
    PubMed     Text format     Abstract available

  15. EL-MATARY W
    Indicators of Quality of Care in Inflammatory Bowel Disease: Seeking the Right Path for Patients.
    Inflamm Bowel Dis. 2017 Mar 21. doi: 10.1097/MIB.0000000000001069.
    PubMed     Text format    

  16. ZULLOW S, Fazelat A, Farraye FA
    Central Serous Chorioretinopathy in a Patient with Ulcerative Colitis with Pouchitis on Budesonide-EC.
    Inflamm Bowel Dis. 2017 Mar 21. doi: 10.1097/MIB.0000000000001091.
    PubMed     Text format    


    J Clin Microbiol

  17. ECK A, de Groot EF, de Meij TG, Welling M, et al
    Robust Microbiota-Based Diagnostics for Inflammatory Bowel Disease.
    J Clin Microbiol. 2017 Mar 22. pii: JCM.00162-17. doi: 10.1128/JCM.00162.
    PubMed     Text format     Abstract available


    J Crohns Colitis

  18. WISNIEWSKI A, Flejou JF, Siproudhis L, Abramowitz L, et al
    Anal neoplasia in Inflammatory Bowel Disease: Classification proposal, epidemiology, carcinogenesis and risk management perspectives.
    J Crohns Colitis. 2017 Mar 10. doi: 10.1093.
    PubMed     Text format     Abstract available

  19. RUIZ DE MORALES JG, Munoz F, Hernando M
    Successful treatment of Common Variable Immunodeficiency-associated inflammatory bowel disease with Ustekinumab.
    J Crohns Colitis. 2017 Feb 17. doi: 10.1093.
    PubMed     Text format    

  20. LEE HS, Oh H, Baek J, Jung S, et al
    X chromosome-wide association study identifies a susceptibility locus for inflammatory bowel disease in Koreans.
    J Crohns Colitis. 2017 Feb 22. doi: 10.1093.
    PubMed     Text format     Abstract available

  21. UCHIYAMA K, Takagi T, Kashiwagi S, Toyokawa Y, et al
    Assessment of endoscopic mucosal healing of ulcerative colitis using linked colour imaging, a novel endoscopic enhancement system.
    J Crohns Colitis. 2017 Feb 22. doi: 10.1093.
    PubMed     Text format     Abstract available

  22. DANESE S, Bonovas S, Peyrin-Biroulet L
    Budesonide MMX Add-on to 5-Aminosalicylic Acid Therapy in Mild-to-Moderate Ulcerative Colitis: A Favourable Risk-Benefit Profile.
    J Crohns Colitis. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format    

  23. UZZAN M, Kirchgesner J, Oubaya N, Amiot A, et al
    Risk of rectal neoplasia after colectomy and ileorectal anastomosis for ulcerative colitis.
    J Crohns Colitis. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  24. Erratum: Use of digital technology to boost patient recruitment in inflammatory bowel disease clinical trials.
    J Crohns Colitis. 2017 Mar 9. doi: 10.1093.
    PubMed     Text format    

  25. ROSARIO M, French JL, Dirks NL, Sankoh S, et al
    Exposure-Efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
    J Crohns Colitis. 2017 Feb 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  26. Corrigendum: The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Mar 9. doi: 10.1093.
    PubMed     Text format    

  27. MOHAMMED K, Shaik NA, Al-Abbasi FA
    Novel de novo mutations of the interleukin-10 receptor gene lead to infantile onset inflammatory bowel disease: A Correction.
    J Crohns Colitis. 2017 Mar 15. doi: 10.1093.
    PubMed     Text format    

  28. CANTORO L, Di Sabatino A, Papi C, Margagnoni G, et al
    The time course of diagnostic delay in inflammatory bowel disease over the last sixty years: an Italian multicentre study.
    J Crohns Colitis. 2017 Mar 17. doi: 10.1093.
    PubMed     Text format     Abstract available

  29. JUNG YS, Han M, Kim WH, Park S, et al
    Cancer risk in the Early Stages of Inflammatory Bowel Disease in Korean patients: A Nationwide Population-based Study.
    J Crohns Colitis. 2017 Mar 16. doi: 10.1093.
    PubMed     Text format     Abstract available

  30. RUBIN DT, Cohen RD, Sandborn WJ, Lichtenstein GR, et al
    Budesonide Multi-Matrix Is Efficacious for Mesalamine-Refractory, Mild to Moderate Ulcerative Colitis: A Randomized, Placebo-Controlled Trial.
    J Crohns Colitis. 2017 Mar 4. doi: 10.1093.
    PubMed     Text format     Abstract available

  31. TAXONERA C, Ponferrada A, Bermejo F, Riestra S, et al
    Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Feb 17. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Gastroenterol

  32. SUZUKI Y, Motoya S, Hanai H, Hibi T, et al
    Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis.
    J Gastroenterol. 2017 Mar 20. doi: 10.1007/s00535-017-1325.
    PubMed     Text format     Abstract available

  33. HIBI T, Imai Y, Senoo A, Ohta K, et al
    Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study).
    J Gastroenterol. 2017 Mar 21. doi: 10.1007/s00535-017-1326.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: